Literature DB >> 2809542

Computer-aided headspace gas chromatography applied to blood-alcohol analysis: importance of online process control.

A W Jones1, J Schuberth.   

Abstract

This paper describes the analysis of ethanol in blood specimens from suspect drunk drivers and the associated quality assurance procedures currently used in Sweden for legal purposes. Aliquots of whole blood from two separate Vacutainer tubes are diluted with 1-propanol as internal standard before analysis by headspace gas chromatography (HS-GC) with three different stationary phases: Carbopak B, Carbopak C, and 15% Carbowax 20 M. The actual HS-GC analysis, the integration of chromatographic peaks, the collection and processing of results, as well as the quality control tests involve the use of computer-aided techniques. The standard deviation of analysis(y) increased with concentration of ethanol in the blood specimen(x), and above 0.50 mg/g the regression equation was y = 0.0033 + 0.0153x. The prosecution blood-alcohol concentration (BAC) is the mean of three separate determinations made by different laboratory technicians working independently with different sets of equipment. A deduction is made from the mean analytical result to compensate for random and systematic errors inherent in the method. At BACs of 0.5 and 1.5 mg/g, which are the statutory limits in Sweden, the allowances currently made are 0.06 and 0.09 mg/g, respectively. Accordingly, the reduced prosecution BAC is less than the actual BAC with a statistical confidence of 99.9%.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2809542

Source DB:  PubMed          Journal:  J Forensic Sci        ISSN: 0022-1198            Impact factor:   1.832


  16 in total

1.  Within- and between-subject variations in pharmacokinetic parameters of ethanol by analysis of breath, venous blood and urine.

Authors:  A Norberg; J Gabrielsson; A W Jones; R G Hahn
Journal:  Br J Clin Pharmacol       Date:  2000-05       Impact factor: 4.335

2.  Pharmacokinetics of ethanol in plasma and whole blood: estimation of total body water by the dilution principle.

Authors:  A W Jones; R G Hahn; H P Stalberg
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

3.  Impact of gastric emptying on the pharmacokinetics of ethanol as influenced by cisapride.

Authors:  S Kechagias; K A Jönsson; A W Jones
Journal:  Br J Clin Pharmacol       Date:  1999-11       Impact factor: 4.335

4.  Lack of effect of omeprazole, cimetidine, and ranitidine on the pharmacokinetics of ethanol in fasting male volunteers.

Authors:  K A Jönsson; A W Jones; H Boström; T Andersson
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

5.  Ultra-rapid rate of ethanol elimination from blood in drunken drivers with extremely high blood-alcohol concentrations.

Authors:  Alan Wayne Jones
Journal:  Int J Legal Med       Date:  2007-06-16       Impact factor: 2.686

Review 6.  Role of variability in explaining ethanol pharmacokinetics: research and forensic applications.

Authors:  Ake Norberg; A Wayne Jones; Robert G Hahn; Johan L Gabrielsson
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

7.  Newer antidepressants: evaluation of fatal toxicity index and interaction with alcohol based on Finnish postmortem data.

Authors:  Anna Koski; Erkki Vuori; Ilkka Ojanperä
Journal:  Int J Legal Med       Date:  2005-03-01       Impact factor: 2.686

8.  Forensic toxicology findings in deaths involving gamma-hydroxybutyrate.

Authors:  Fredrik C Kugelberg; Anita Holmgren; Arne Eklund; Alan Wayne Jones
Journal:  Int J Legal Med       Date:  2008-12-02       Impact factor: 2.686

9.  Between-subject and within-subject variations in the pharmacokinetics of ethanol.

Authors:  A W Jones; K A Jönsson
Journal:  Br J Clin Pharmacol       Date:  1994-05       Impact factor: 4.335

10.  Faster absorption of ethanol and higher peak concentration in women after gastric bypass surgery.

Authors:  H Klockhoff; I Näslund; A W Jones
Journal:  Br J Clin Pharmacol       Date:  2002-12       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.